Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014–2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic
{"title":"Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014–2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic","authors":"Noriko Takeuchi , Bin Chang , Naruhiko Ishiwada , Yoshiaki Cho , Junichiro Nishi , Kenji Okada , Mikiya Fujieda , Megumi Oda , Akihiko Saitoh , Mitsuaki Hosoya , Nobuhisa Ishiguro , Kohei Takahashi , Yoshihito Ozawa , Shigeru Suga","doi":"10.1016/j.vaccine.2025.127138","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Nationwide surveillance was conducted in Japan to clarify the status of pediatric invasive pneumococcal diseases (IPD) after introducing a 13-valent pneumococcal conjugate vaccine (PCV13).</div></div><div><h3>Methods</h3><div>Detailed clinical and epidemiologic information of IPD cases in children aged <15 years was collected from 10 of 47 prefectures in Japan from January 2014 to December 2022. <em>Streptococcus pneumoniae</em> strains isolated from sterile body sites were analyzed including capsular serotypes, multi-locus sequence typing (MLST), and antimicrobial susceptibility testing. The serotype-specific IPD incidence was calculated by imputing the serotypes for missing isolates to serotypes assumed based on the distribution of known serotypes.</div></div><div><h3>Results</h3><div>During the study period, 1033 IPD cases were reported. The incidence rate of total IPD in patients aged <5 years from 2014 to 2019 declined by 21.3 % compared with the rate from 2011 to 2013 before the introduction of PCV13. Compared with the incidence of total IPD from 2014 to 2019 and from 2020 to 2022, during the COVID-19 pandemic, the incidence of IPD among children aged <5 years declined by 49.7 %. In total, 932 IPD cases were identified as capsular serotypes. Among children aged <5 years, the most frequent serotype was 24F, followed by 15 A, 12F, 15C, 15B, and 10 A. Since 2014, after replacement with PCV13 in 2013, the rate of IPD by PCV13 minus PCV7 serotypes decreased, and non-PCV13 serotypes further increased. The serotype causing IPD in children aged <5 years, with PCV15-unique serotypes and PCV20-unique serotype were 8.6 % and 22.5 %, respectively. In terms of antimicrobial susceptibility, strains resistant to penicillin and cefotaxime decreased, whereas the meropenem non-susceptible strains increased in the post-PCV13 era.</div></div><div><h3>Conclusion</h3><div>PCV13 introduction and the COVID-19 pandemic have had a significant impact on pediatric IPD in Japan. It is important to continuously monitor the epidemiological characteristics of pediatric IPD after the introduction of PCV20.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127138"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25004359","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Nationwide surveillance was conducted in Japan to clarify the status of pediatric invasive pneumococcal diseases (IPD) after introducing a 13-valent pneumococcal conjugate vaccine (PCV13).
Methods
Detailed clinical and epidemiologic information of IPD cases in children aged <15 years was collected from 10 of 47 prefectures in Japan from January 2014 to December 2022. Streptococcus pneumoniae strains isolated from sterile body sites were analyzed including capsular serotypes, multi-locus sequence typing (MLST), and antimicrobial susceptibility testing. The serotype-specific IPD incidence was calculated by imputing the serotypes for missing isolates to serotypes assumed based on the distribution of known serotypes.
Results
During the study period, 1033 IPD cases were reported. The incidence rate of total IPD in patients aged <5 years from 2014 to 2019 declined by 21.3 % compared with the rate from 2011 to 2013 before the introduction of PCV13. Compared with the incidence of total IPD from 2014 to 2019 and from 2020 to 2022, during the COVID-19 pandemic, the incidence of IPD among children aged <5 years declined by 49.7 %. In total, 932 IPD cases were identified as capsular serotypes. Among children aged <5 years, the most frequent serotype was 24F, followed by 15 A, 12F, 15C, 15B, and 10 A. Since 2014, after replacement with PCV13 in 2013, the rate of IPD by PCV13 minus PCV7 serotypes decreased, and non-PCV13 serotypes further increased. The serotype causing IPD in children aged <5 years, with PCV15-unique serotypes and PCV20-unique serotype were 8.6 % and 22.5 %, respectively. In terms of antimicrobial susceptibility, strains resistant to penicillin and cefotaxime decreased, whereas the meropenem non-susceptible strains increased in the post-PCV13 era.
Conclusion
PCV13 introduction and the COVID-19 pandemic have had a significant impact on pediatric IPD in Japan. It is important to continuously monitor the epidemiological characteristics of pediatric IPD after the introduction of PCV20.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.